Aeromedical Medication Compatibility Review Note

Date/Time: [Date and time with time zone] (Use 24-hour format; time zone critical for no-fly interval calculations)

Author: [Name, credentials, clinic/organization]

Patient: [Name, DOB, identifiers per local policy]

Encounter Type: [in-person / telehealth / chart review]

Data Sources: [Patient report, EHR medication list, pharmacy records, specialist notes, other] (List only sources actually used)

Reason for Review

[Trigger for review: new medication start, dose change, PRN use event, adverse effect report, post-procedure medications, return-to-duty request, periodic flight status review] (Include timing if relevant)

Operational Context

• Role: [pilot / air traffic control specialist / cabin crew / UAS operator / other safety-sensitive]
• Certificate/Class: [Certificate class or status] (If unknown, state explicitly and recommend confirmation with AME or employer)
• Duty Profile: [single-pilot / multi-crew], [day / night / mixed ops], [typical mission duration] (Summarize operational demands relevant to fatigue and cognitive load)
• Policy Constraints: [Known employer or agency medication restrictions] (Include only if provided)
• Urgency: [Imminent duty timeline if applicable]

Clinical Background

(Create a separate paragraph for each relevant underlying condition treated by the medication(s) under review.)

[Condition and Diagnosis]: [Acute vs chronic], [stable vs unstable]. [Current symptom burden and functional impact, emphasizing aeromedically relevant symptoms: sedation, dizziness, cognitive impairment, visual disturbance, palpitations, syncope risk, hypoglycemia, GI urgency]. [Operational risk if symptoms recur or medication fails mid-duty].

Targeted Aeromedical Review of Systems: [CNS: sedation, slowed thinking, dizziness/vertigo]; [Vision: blurred vision, diplopia]; [Cardiovascular: palpitations, orthostasis]; [GI: nausea, urgency]; [Sleep quality]; [ENT/barotrauma risk] (Include only domains relevant to this case)

Current Medications

(List all current medications. If any detail is unknown, especially last dose timing, explicitly note as Unknown and add action item in Plan to confirm before determining no-fly interval.)

• [Medication name (generic)]: [Dose], [frequency: scheduled vs PRN], [route], [formulation: IR/ER], [indication], [start date], [date of most recent dose change], [prescriber or self-directed OTC]. Last dose: [Date/time with time zone / Unknown]. Side effects reported: [List or none reported].

(Repeat for each medication)

Co-use and Substances: [Alcohol, sedatives, cannabis/CBD, "PM" combination products, high caffeine intake] (State presence or absence; quantify if provided)

Drug Allergies and Adverse Reactions: [Allergen and reaction details including severity]

Medication Compatibility Review

(Create a subsection for each medication under review. Provide detailed assessment for higher-risk agents; use abbreviated entries for clearly low-risk, stable medications.)

[Medication Name]

• Regimen: [Formulation: IR/ER], [current dose and frequency], [indication], [on-label / off-label use]
• Effectiveness and Stability: [Symptoms controlled or not], [duration on current dose], [recent or planned changes]
• Side Effect and Impairment Screen: [Document presence or absence of: sedation/drowsiness, slowed reaction time, cognitive fog, dizziness/vertigo, blurred vision, orthostasis, palpitations, GI urgency, tremor, insomnia]. (If medication class may impair without subjective awareness, note as counseling point.)
• Interaction Risk: [Additive CNS depressants: present/absent], [sympathomimetic stacking: present/absent], [OTC ingredient overlap: present/absent]. (If assessment limited by incomplete data, document limitation.)
• Observation Times and No-Fly Intervals:
  • Ground trial: [Complete / In progress / Not started] — [Start date/time with time zone] to [end date/time with time zone]; side effects observed: [Yes with details / No]
  • Post-dose no-fly interval: [Required wait time]. Calculation method: [medication-specific guidance / 5× half-life / 5× dosing interval]. Last dose: [Date/time with time zone]. Earliest return-to-duty: [Date/time with time zone]. (If authoritative guidance not verified, recommend conservative restriction and AME consultation.)
• Acceptability: [Generally acceptable / Conditionally acceptable with specified restrictions / Unacceptable or requires aeromedical authority clearance]. (If indication differs from commonly accepted aeromedical use cases, flag explicitly.)

(Repeat subsection for each medication under review)

Integrated Risk Assessment

[Synthesis of overall aeromedical risk considering: medication impairment potential, underlying condition severity and stability, interaction/polypharmacy risks, and operational context demands].

Conclusion: [Appropriate / Not appropriate] to resume [aviation / safety-sensitive] duties at this time. [Specify whether restriction is due to medication, underlying condition, or both].

• Restriction period: [No-fly / no-safety-sensitive-duty] from [start date/time with time zone] to [end date/time with time zone or until criteria met]
• Conditional return criteria: [Symptom-free, no side effects, stable dose for specified duration, follow-up completed]
• Escalation triggers requiring re-evaluation: [Sedation, dizziness, palpitations, visual changes, syncope, other]

Patient Counseling

• [Self-assessment guidance and "do not fly if" criteria related to underlying condition symptoms]
• [Instruction to read medication labels and avoid products with drowsiness or "operate machinery" warnings unless reviewed]
• [Complete ground trials before duty; do not trial new medications immediately before duty periods]
• [Prefer single-ingredient OTC products; avoid "PM/nighttime" multi-symptom products unless explicitly reviewed]
• [Patient acknowledgment or teach-back confirming understanding of restrictions and no-fly intervals]

Plan

• Medication adjustments: [Recommended changes with rationale; safer alternatives if applicable]
• Monitoring: [What to monitor, frequency, by whom]
• Follow-up: [Timing, mode, reassessment focus]
• AME/Aeromedical authority consultation: [Recommended / Not needed] (If recommended, specify timeline)
• Prescriber coordination: [Communication planned with treating prescriber if medication change suggested]
• Missing data to confirm: [List any safety-critical unknowns requiring clarification before finalizing no-fly interval]
• Guidance referenced: [Authority/source consulted, version, access date]

Disclaimer: This document provides a clinical medication compatibility assessment and recommended operational restrictions. It does not determine or guarantee aeromedical certification outcomes. The individual should consult their Aviation Medical Examiner or relevant aeromedical authority for certification decisions.

(Omit sections with no relevant content. Do not infer or assert "no side effects," "safe to fly," or "approved" status without explicit patient report or verified source documentation.)